Company intelligence / Profile preview

Tigen Pharma

Epalinges, Vaud, Switzerland

Ownership: Private
Development stage: Other

Overview

Tigen Pharma is conducting clinical programs in partnership with leading institutions (including Memorial Sloan Kettering) focused on decentralized, non-viral CAR-T therapy in hematologic malignancies. Early-stage studies are ongoing, and its lead program (for AML) employs armored-CAR technology in collaboration with MSKCC[4].

Therapeutic areas: OncologyHematology
Modalities: Cell therapyCAR-T cell therapy
Industry: Biotech

Drug pipeline

3 assets

NeoTIL

2 more assets in the full pipeline.

Request access →

Partnerships

Memorial Sloan Kettering Cancer Center (MSKCC)

Beyond the preview

Go deeper on Tigen Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tigen Pharma.

Explore the full profile